skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

There have been 78 comments on the European Commission’s public consultation on its draft implementing regulation on the electronic provision of instructions for use (IFU) for medical technology.

It will be interesting to see the extent to which these comments impact the outcome of this document, not least because there are such diverging views.

The draft brings the former version of the eIFU regulation EU 207/2012 into the framework of the Medical Device Regulation at the same time as updating the rules. (The Regulation EU 207/2012 applies to electronic IFU for products that comply with the medical device directives.)

The new proposed draft implementing regulation now also suggests allowing online manuals instead of paper instructions for medical device software.

What The Responses Call For

The 78 responses to the public consultation are split between those demanding that paper instructions are needed because they are much more reliable and readily accessible in a health care situation, and those who want to see electronic instructions for use (eIFU) for all professional-use medical technology, including medical device software.

Some go even further. Cochlear of Australia, for example, calls on the commission to consider expanding the scope of the regulation to all products, not just those used by health care professionals.

Where Rules Permit eIFU – Now And In Future

Economic operators have been allowed to provide online manuals instead of paper instructions for certain device categories for nearly a decade in the context of the medical device directives. But while eIFU alone are permitted for some professional use devices, under the eIFU regulation EU 207/2012, they are not permitted in the case of devices for patient use.

Providing IFU in electronic form for these devices is only permitted where the devices and accessories are intended exclusively for use by professionals, and where use by other persons is not reasonably foreseeable. There must always still be the option for professionals to request and to receive a physical copy of the IFU.

The same policy is suggested under the MDR. The implementing regulation suggests that manufacturers may provide IFU in electronic form instead of in paper form for the following devices under the MDR:

  • Implantable and active implantable medical devices and their accessories;

  • Fixed installed medical devices;

  • Medical devices and their accessories fitted with a built-in system visually displaying the IFU; and

  • Software covered by the MDR where manufacturers may provide eIFU by means of the software itself instead of in paper form.

The Argument Against eIFU

In general, it is mainly individual citizens (some from the EU but not all) who object to eIFU. Some express concern that the IFU should be “trusted source,” not least for older and disabled people who may struggle to have access to electronic instructions. They also fear risks from scam websites, among other things.

The European Association of Hospital Pharmacists (EAHP), meanwhile, commented in the consultation on how useful it is for health care professionals to have such information electronically. It stressed how “any electronic instructions for use of medical devices need to be assessed and accepted by regulatory authorities in the same way that happens with paper instructions.”

There were also arguments in favor of printed IFU from print companies, as would be expected. Heidelberger Druckmaschinen of Germany argues that printed information ensures there are no access problems for all groups of users. “Moreover,” it says, “printed information limits the risk of cyberattacks on health-related infrastructure that may fake information or shutdown relevant systems.”

Apps And Eudamed Repository

One EU citizen commented that “It would be great if there could be an exception for software that is distributed via digital channels (website, appstore) even though it is intended to be used by laypeople/patients.”

Another suggested that it would be useful to make eIFU documents available within the Eudamed medical device database.

MedTech Europe Response

Responding on behalf of the medtech industry, EU industry association, MedTech Europe reiterates its call for eIFU to be extended to all professional use medical devices. It had already laid out its argument in a document in February 2020.

In a 10-page attachment which forms its response to the consultation it observes, among other things, that numerous other countries around the world allow eIFU for professional use, including Australia, USA, Canada, Saudi Arabia, Brazil, and Serbia.

The industry association asserts that there are no new risks by extending the scope of the regulation to include all professional use devices, and that eIFU will help streamline regulatory procedures under the MDR.

 Its arguments include:

  • Member state authorities will have direct access to eIFU during the review of vigilance cases and field safety correction action (FSCA) notifications in their territory; and

  • Field safety notices (FSNs) that include labeling updates as part of a corrective action can be immediately distributed to professional users, rather than waiting for physical delivery to reach the final user at their hospital or clinic.

Environmental Impact

When it comes to the environmental impact, the jury seems to be out on whether eIFU provision is better than paper instructions. Many argue that, because of the technical nature of medtech products, multiple copies of lengthy paper IFU are printed out in situ in a way that has a much higher environmental footprint than were they printed by professional organizations who benefit from more environmentally friendly techniques.

Read also

;

Next steps

Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: